Neutropenia
Conditions
Brief summary
Prospective, multicenter, non-interventional registration studies were used in this project . Eight hundreds patients with solid tumors who met the inclusion criteria in six hospitals in Sichuan Province, Sichuan Province, were selected from the first chemotherapy cycle using PEG-rhG-CSF (can be any chemotherapy cycle of the patient), and each subsequent chemotherapy cycle was recorded. The use of PEG-rhG-CSF and related patient outcomes until the end of chemotherapy. Analyze the clinical practice of using PEG-rhG-CSF in the real world.
Interventions
DRUGPegfilgrastim（PEG-rhG-CSF）
From the first chemotherapy cycle using PEG-rhG-CSF (which can be any chemotherapy cycle of the patient), record the use of PEG-rhG-CSF in this cycle and each subsequent chemotherapy cycle, including dosage, administration time and dosing frequency
Sponsors
Affiliated Hospital of North Sichuan Medical College
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
1. Age ≥ 18 years old; 2. Diagnosed as a malignant solid tumor by histology and cytology, requiring chemotherapy patients; 3. The first use of PEG-rhG-CSF during the chemotherapy cycle (not limited to the first chemotherapy cycle, can be any chemotherapy cycle of the patient); 4. Subjects volunteered to participate in this clinical trial and signed informed consent.
Exclusion criteria
1. PEG-rhG-CSF was used in the current chemotherapy cycle; 2. Have received hematopoietic stem cell transplantation or bone marrow transplantation; 3. Other drug clinical trials are currently underway.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dosage of PEG-rhG-CSF in chemotherapy | 1 YEAR |
| Administration time of PEG-rhG-CSF in chemotherapy | 1 YEAR |
| dosing frequency of PEG-rhG-CSF in chemotherapy | 1 YEAR |
Countries
China
Contacts
Primary ContactXian Bang Tan
Outcome results
None listed